Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Hepatitis C

  Free Subscription


Articles published in Gastroenterology

Retrieve available abstracts of 93 articles:
HTML format
Text format



Single Articles


    April 2019
  1. LUPBERGER J, Croonenborghs T, Roca Suarez AA, Van Renne N, et al
    Combined Analysis of Metabolomes, Proteomes, and Transcriptomes of HCV-infected Cells and Liver to Identify Pathways Associated With Disease Development.
    Gastroenterology. 2019 Apr 9. pii: S0016-5085(19)35670.
    PubMed     Text format     Abstract available


    March 2019
  2. SINGAL AG, Lim JK, Kanwal F
    AGA Clinical Practice Update on Interaction between Oral Direct-Acting Antivirals (DAAs) for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review.
    Gastroenterology. 2019 Mar 13. pii: S0016-5085(19)33558.
    PubMed     Text format    


  3. HAMDANE N, Juhling F, Crouchet E, El Saghire H, et al
    HCV-induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response.
    Gastroenterology. 2019 Mar 2. pii: S0016-5085(19)32506.
    PubMed     Text format     Abstract available


    February 2019
  4. TORRES HA, Pundhir P, Mallet V
    Hepatitis C virus infection in patients with cancer: impact on clinical trial enrollment, selection of therapy, and prognosis.
    Gastroenterology. 2019 Feb 21. pii: S0016-5085(19)30435.
    PubMed     Text format    


  5. CACOUB P
    Hepatitis C Virus Infection, a New Modifiable Cardiovascular Risk Factor.
    Gastroenterology. 2019 Feb 15. pii: S0016-5085(19)30382.
    PubMed     Text format    


  6. THABUT D, Bureau C, Layese R, Bourcier V, et al
    Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients with Compensated Cirrhosis and a Sustained Response to Antiviral Therapy.
    Gastroenterology. 2019 Feb 12. pii: S0016-5085(18)35303.
    PubMed     Text format     Abstract available


    January 2019
  7. SALEM G, Adhikari LJ
    Hepatitis C, and Cannot See!
    Gastroenterology. 2019 Jan 2. pii: S0016-5085(18)35432.
    PubMed     Text format    


    December 2018
  8. VERGARA C, Thio CL, Johnson E, Kral AH, et al
    Multi-Ancestry Genome-Wide Association Study of Spontaneous Clearance of Hepatitis C Virus.
    Gastroenterology. 2018 Dec 26. pii: S0016-5085(18)35421.
    PubMed     Text format     Abstract available


  9. ALTER HJ, Chisari FV
    Is Elimination of Hepatitis B and C a Pipe Dream or Reality?
    Gastroenterology. 2018 Dec 26. pii: S0016-5085(18)35422.
    PubMed     Text format    


    November 2018
  10. BUTT AA, Yan P, Shuaib A, Abou-Samra AB, et al
    Direct-acting Antiviral Therapy for HCV Infection is Associated with a Reduced Risk of Cardiovascular Disease Events.
    Gastroenterology. 2018 Nov 13. pii: S0016-5085(18)35264.
    PubMed     Text format     Abstract available


  11. WARD JW, Hinman AR
    What is Needed to Eliminate Hepatitis B Virus and Hepatitis C Virus as Global Health Threats.
    Gastroenterology. 2018 Nov 1. pii: S0016-5085(18)35205.
    PubMed     Text format     Abstract available


  12. NAGAI S, Chau LC, Schilke RE, Safwan M, et al
    Effects of Allocating Livers for Transplantation Based on Model for End-Stage Liver Disease-Sodium Scores on Patient Outcomes.
    Gastroenterology. 2018;155:1451-1462.
    PubMed     Text format     Abstract available


    October 2018
  13. IOANNOU GN, Feld JJ
    What are the Benefits of a Sustained Virologic Response to Direct-acting Antiviral Therapy for HCV Infection?
    Gastroenterology. 2018 Oct 24. pii: S0016-5085(18)35166.
    PubMed     Text format     Abstract available


  14. BAUMERT TF, Berg T, Lim JK, Nelson DR, et al
    Status of Direct-acting Antiviral Therapy for HCV Infection and Remaining Challenges.
    Gastroenterology. 2018 Oct 17. pii: S0016-5085(18)35155.
    PubMed     Text format     Abstract available


  15. VISENTINI M, Fiorilli M, Casato M
    Persistence of pathogenic B cell clones and relapse of cryoglobulinemic vasculitis in HCV-cured patients.
    Gastroenterology. 2018 Oct 10. pii: S0016-5085(18)35150.
    PubMed     Text format    


  16. O'BRIEN TR, Yang HI, Groover S, Jeng WJ, et al
    Genetic Factors That Affect Spontaneous Clearance of Hepatitis C or B Virus, Response to Treatment, and Disease Progression.
    Gastroenterology. 2018 Oct 1. pii: S0016-5085(18)35083.
    PubMed     Text format     Abstract available


  17. KIM D, Li AA, Gadiparthi C, Khan MA, et al
    Changing Trends in Etiology-Based Annual Mortality From Chronic Liver Disease, From 2007 Through 2016.
    Gastroenterology. 2018;155:1154-1163.
    PubMed     Text format     Abstract available


  18. PERRY I, Patel D
    Hemoptysis: Call the Gastroenterologist?
    Gastroenterology. 2018;155:e1-e2.
    PubMed     Text format    


    September 2018
  19. BAILEY JR, Barnes E, Cox AL
    Approaches, Progress, and Challenges to Hepatitis C Vaccine Development.
    Gastroenterology. 2018 Sep 26. pii: S0016-5085(18)35035.
    PubMed     Text format     Abstract available


  20. REHERMANN B, Thimme R
    Insights From Antiviral Therapy into Immune Responses to HBV and HCV Infection.
    Gastroenterology. 2018 Sep 26. pii: S0016-5085(18)35037.
    PubMed     Text format     Abstract available


  21. JACOBSON IM
    Re: Sofosbuvir, Velpatasvir, and Ribavirin in HCV.
    Gastroenterology. 2018 Sep 8. pii: S0016-5085(18)34936.
    PubMed     Text format    


    August 2018
  22. BOYER A, Park SB, de Boer Y, Li Q, et al
    TM6SF2 Promotes Lipidation and Secretion of Hepatitis C Virus in Infected Hepatocytes.
    Gastroenterology. 2018 Aug 22. pii: S0016-5085(18)34892.
    PubMed     Text format     Abstract available


  23. OJHA RP, MacDonald BR, Chu TC, Marcus JL, et al
    Potential Overestimation of Racial Disparities in Response to the 8-Week Ledipasvir/Sofosbuvir Regimen for Hepatitis C Virus Genotype 1 Infection.
    Gastroenterology. 2018 Aug 14. pii: S0016-5085(18)34876.
    PubMed     Text format    


    July 2018
  24. LUNEMANN S, Schobel A, Kah J, Fittje P, et al
    Interactions Between KIR3DS1 and HLA-F Activate Natural Killer Cells to Control HCV Replication in Cell Culture.
    Gastroenterology. 2018 Jul 19. pii: S0016-5085(18)34785.
    PubMed     Text format     Abstract available


  25. NAHON P, Layese R, Bourcier V, Cagnot C, et al
    Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs.
    Gastroenterology. 2018 Jul 18. pii: S0016-5085(18)34781.
    PubMed     Text format     Abstract available


  26. KOH S, Kah J, Tham CYL, Yang N, et al
    Nonlytic Lymphocytes Engineered to Express Virus-Specific T-Cell Receptors Limit HBV Infection by Activating APOBEC3.
    Gastroenterology. 2018;155:180-193.
    PubMed     Text format     Abstract available


    June 2018
  27. ESTEBAN R, Pineda JA, Calleja JL, Casado M, et al
    Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With HCV genotype 3 Infection and Cirrhosis.
    Gastroenterology. 2018 Jun 26. pii: S0016-5085(18)34684.
    PubMed     Text format     Abstract available


    May 2018
  28. GARDINI AC, Conti F, Brillanti S, Andreone P, et al
    Imbalance of Neutrophils and Lymphocyte Counts Can Be Predictive of Hepatocellular Carcinoma Occurrence in Hepatitis C-related Cirrhosis Treated With Direct-acting Antivirals.
    Gastroenterology. 2018 May 7. pii: S0016-5085(18)30419.
    PubMed     Text format    


  29. MOORMAN AC, Xing J, Nelson NP
    Need for Increasing Hepatitis A Virus Vaccination Among Patients Infected With Hepatitis B Virus and Hepatitis C Virus.
    Gastroenterology. 2018 May 3. pii: S0016-5085(18)34481.
    PubMed     Text format    


  30. COSTENTIN C, Layese R, Bourcier V, Cagnot C, et al
    Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-time Adjusted Survival of Patients With Compensated Viral Cirrhosis.
    Gastroenterology. 2018 May 2. pii: S0016-5085(18)30488.
    PubMed     Text format     Abstract available


    April 2018
  31. BONACCI M, Lens S, Marino Z, Londono MC, et al
    Long-Term Outcomes of Patients With HCV-Associated Cryoglobulinemic Vasculitis After Virologic Cure.
    Gastroenterology. 2018 Apr 26. pii: S0016-5085(18)30485.
    PubMed     Text format     Abstract available


  32. CALVARUSO V, Cabibbo G, Cacciola I, Petta S, et al
    Incidence of Hepatocellular Carcinoma in Patients with HCV-associated Cirrhosis Treated with Direct-Acting Antiviral Agents.
    Gastroenterology. 2018 Apr 12. pii: S0016-5085(18)30441.
    PubMed     Text format     Abstract available


  33. MORSE A, Barritt AS 4th, Jhaveri R
    Individual State Hepatitis C Data Supports Expanding Screening Beyond Baby Boomers to All Adults.
    Gastroenterology. 2018 Apr 2. pii: S0016-5085(18)30304.
    PubMed     Text format    


  34. SCOTT RA, Aithal GP, Francis ST, Irving WL, et al
    Pretreatment Lesions on Magnetic Resonance Imaging in Patients With Hepatitis C Virus Infection Diagnosed With Hepatocellular Carcinoma After Initiating Direct-Acting Antiviral Therapy.
    Gastroenterology. 2018 Apr 2. pii: S0016-5085(18)30305.
    PubMed     Text format    


    March 2018
  35. GRUNVOGEL O, Colasanti O, Lee JY, Kloss V, et al
    Secretion of Hepatitis C Virus Replication Intermediates Reduces Activation of Toll Like Receptor 3 in Hepatocytes.
    Gastroenterology. 2018 Mar 10. pii: S0016-5085(18)30309.
    PubMed     Text format     Abstract available


  36. EL-SHERIF O, Jiang ZG, Tapper EB, Huang KC, et al
    Baseline Factors Associated with Improvements in Decompensated Cirrhosis After Direct-acting Antiviral Therapy for HCV Infection.
    Gastroenterology. 2018 Mar 10. pii: S0016-5085(18)30314.
    PubMed     Text format     Abstract available


  37. PONZETTO A, Figura N
    Risk of Hepatocellular Carcinoma After Cure of Hepatitis C Virus.
    Gastroenterology. 2018 Mar 8. pii: S0016-5085(18)30153.
    PubMed     Text format    


  38. LO GH
    The Elevation of Hepatic Venous Pressure Gradient After Sustained Virologic Response in Hepatitis C Virus-Related Cirrhosis.
    Gastroenterology. 2018 Mar 8. pii: S0016-5085(18)30148.
    PubMed     Text format    


  39. MANDORFER M, Reiberger T, Peck-Radosavljevic M
    Monitoring the Evolution of Portal Hypertension After Sustained Virologic Response.
    Gastroenterology. 2018 Mar 8. pii: S0016-5085(18)30150.
    PubMed     Text format    


    February 2018
  40. PHAM LV, Ramirez S, Gottwein JM, Fahnoe U, et al
    HCV Genotype 6a Escape from and Resistance to Velpatasvir, Pibrentasvir, and Sofosbuvir in Robust Infectious Cell Culture Models.
    Gastroenterology. 2018 Feb 15. pii: S0016-5085(18)30212.
    PubMed     Text format     Abstract available


  41. TEDESCO D, Thapa M, Chin CY, Ge Y, et al
    Alterations in Intestinal Microbiota Lead to Production of Interleukin 17 by Intrahepatic gammadelta T-cell Receptor-positive Cells and Pathogenesis of Cholestatic Liver Disease.
    Gastroenterology. 2018 Feb 15. pii: S0016-5085(18)30214.
    PubMed     Text format     Abstract available


  42. MA AT, Feld JJ
    Hepatitis B Reactivation With Hepatitis C Treatment: Bringing Some Clarity to the Black Box.
    Gastroenterology. 2018 Feb 6. pii: S0016-5085(18)30161.
    PubMed     Text format    


  43. TAVIS JE, Lomonosova E
    NVR 3-778 Plus Pegylated Interferon-alpha Treatment for Chronic Hepatitis B Viral Infections: Could 1 + 1 = 3?
    Gastroenterology. 2018;154:481-482.
    PubMed     Text format    


    January 2018
  44. MUTZ P, Metz P, Lempp FA, Bender S, et al
    HBV Bypasses the Innate Immune Response and Does not Protect HCV From Antiviral Activity of Interferon.
    Gastroenterology. 2018 Jan 31. pii: S0016-5085(18)30112.
    PubMed     Text format     Abstract available


  45. AGHEMO A, Colombo M
    Glecaprevir/Pibrentasvir: The Final Piece in the Hepatitis C Virus Treatment Puzzle?
    Gastroenterology. 2018 Jan 31. pii: S0016-5085(18)30100.
    PubMed     Text format    


  46. YOSHIKAWA T, Ohana M, Fukuda A
    High fever after radiofrequency ablation of hepatocellular carcinoma.
    Gastroenterology. 2018 Jan 31. pii: S0016-5085(18)30134.
    PubMed     Text format    


  47. MOORMAN AC, Xing J, Rupp LB, Gordon SC, et al
    Hepatitis B Virus Infection and Hepatitis C Virus Treatment in a Large Cohort of Hepatitis C-Infected Patients in the United States.
    Gastroenterology. 2018 Jan 19. pii: S0016-5085(17)36689.
    PubMed     Text format    


    December 2017
  48. GOTTWEIN JM, Pham LV, Mikkelsen LS, Ghanem L, et al
    Efficacy of NS5A Inhibitors Against Hepatitis C Virus Genotypes 1-7 and Escape Variants.
    Gastroenterology. 2017 Dec 21. pii: S0016-5085(17)36720.
    PubMed     Text format     Abstract available


    November 2017
  49. LIU CJ, Chuang WL, Sheen IS, Wang HY, et al
    Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected with HBV.
    Gastroenterology. 2017 Nov 21. pii: S0016-5085(17)36369.
    PubMed     Text format     Abstract available


  50. SHERMAN KE, Shah VH
    Viral Hepatitis: Knowledge and Treatments for HBV/HCV and Associated Transplantation and Neoplasia.
    Gastroenterology. 2017 Nov 14. pii: S0016-5085(17)36348.
    PubMed     Text format    


  51. DIETZ J, Susser S, Vermehren J, Peiffer KH, et al
    Patterns of Resistance-associated Substitutions in Patients With Chronic HCV Infection Following Treatment with Direct-acting Antivirals.
    Gastroenterology. 2017 Nov 13. pii: S0016-5085(17)36353.
    PubMed     Text format     Abstract available


  52. DEBES JD, van Tilborg M, Groothuismink ZMA, Hansen BE, et al
    Levels of Cytokines in Serum Associate With Development of Hepatocellular Carcinoma in Patients With HCV Infection Treated With Direct-acting Antivirals.
    Gastroenterology. 2017 Nov 1. pii: S0016-5085(17)36295.
    PubMed     Text format     Abstract available


    October 2017
  53. RATTAY T, Dumont P, Heinzow HS, Hutton DW, et al
    Cost-effectiveness of Access Expansion to Treatment of Hepatitis C Virus Infection Through Primary Care Providers.
    Gastroenterology. 2017 Oct 23. pii: S0016-5085(17)36275.
    PubMed     Text format     Abstract available


  54. JOHN M, Metwally M, Mangia A, Romero-Gomez M, et al
    TLL1 rs17047200 Increases the Risk of Fibrosis Progression in Caucasian Patients With Chronic Hepatitis C.
    Gastroenterology. 2017 Oct 6. pii: S0016-5085(17)36134.
    PubMed     Text format    


  55. MONDELLI MU
    Liver MAIT Cells in Hepatitis C: Pathogenetic Role or Innocent Bystanders?
    Gastroenterology. 2017 Oct 4. pii: S0016-5085(17)36186.
    PubMed     Text format    


    September 2017
  56. CHILDS-KEAN LM, Hong J
    Detectable Viremia at the End of Treatment With Direct-Acting Antivirals Can Be Associated With Subsequent Clinical Cure in Patients With Chronic Hepatitis C: A Case Series.
    Gastroenterology. 2017 Sep 4. pii: S0016-5085(17)35912.
    PubMed     Text format    


    August 2017
  57. MAAN R, Feld JJ
    Risk for hepatocellular carcinoma after HCV antiviral therapy with direct-acting antivirals: case closed?
    Gastroenterology. 2017 Aug 31. pii: S0016-5085(17)36085.
    PubMed     Text format    


  58. YU ML
    Resistance-Associated Substitutions in Short Duration of Interferon-Free Direct-Acting Antivirals for Hepatitis C.
    Gastroenterology. 2017 Aug 3. pii: S0016-5085(17)35886.
    PubMed     Text format    


  59. BOLTE FJ, O'Keefe AC, Webb LM, Serti E, et al
    Intra-hepatic Depletion of Mucosal Associated Invariant T cells in Hepatitis C Virus-induced Liver Inflammation.
    Gastroenterology. 2017 Aug 2. pii: S0016-5085(17)35975.
    PubMed     Text format     Abstract available


    July 2017
  60. MISHRA P, Florian J, Peter J, Vainorius M, et al
    Public-Private Partnership: Targeting Real-World Data for Hepatitis C Direct-Acting Antivirals.
    Gastroenterology. 2017 Jul 27. pii: S0016-5085(17)35956.
    PubMed     Text format    


  61. LENS S, Alvarado E, Marino Z, Londono MC, et al
    Effects of All-oral Anti-viral Therapy on HVPG and Systemic Hemodynamics in Patients with Hepatitis C Virus-associated Cirrhosis.
    Gastroenterology. 2017 Jul 19. pii: S0016-5085(17)35922.
    PubMed     Text format     Abstract available


    June 2017
  62. KANWAL F, Kramer J, Asch SM, Chayanupatkul M, et al
    Risk of Hepatocellular Cancer in HCV Patients Treated with Direct Acting Antiviral Agents.
    Gastroenterology. 2017 Jun 19. pii: S0016-5085(17)35797.
    PubMed     Text format     Abstract available


  63. ENOMOTO M, Murakami Y, Kawada N
    Detection of HCV RNA in Sustained Virologic Response to Direct-Acting Antiviral Agents: Occult or Science Fiction?
    Gastroenterology. 2017 Jun 2. pii: S0016-5085(17)35638.
    PubMed     Text format    


  64. DE MARCO L, Pellicano R
    When to Search for Occult Infection After Eradication of Hepatitis C?
    Gastroenterology. 2017 Jun 2. pii: S0016-5085(17)35601.
    PubMed     Text format    


    May 2017
  65. KANWAL F, Bacon BR, Beste LA, Brill JV, et al
    Hepatitis C Virus Infection Care Pathway-A Report From the American Gastroenterological Association Institute HCV Care Pathway Work Group.
    Gastroenterology. 2017;152:1588-1598.
    PubMed     Text format    


  66. SINGH S, Muir AJ, Dieterich DT, Falck-Ytter YT, et al
    American Gastroenterological Association Institute Technical Review on the Role of Elastography in Chronic Liver Diseases.
    Gastroenterology. 2017;152:1544-1577.
    PubMed     Text format     Abstract available


    April 2017
  67. LAIDLAW SM, Marukian S, Gilmore RH, Cashman SB, et al
    Tumor Necrosis Factor Inhibits Spread of Hepatitis C Virus Among Liver Cells, Independent from Interferons.
    Gastroenterology. 2017 Apr 26. pii: S0016-5085(17)35530.
    PubMed     Text format     Abstract available


  68. JACOBSON IM, Lawitz E, Gane EJ, Willems BE, et al
    Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir In Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials.
    Gastroenterology. 2017 Apr 5. pii: S0016-5085(17)35399.
    PubMed     Text format     Abstract available


    March 2017
  69. JACOBSON IM, Lim JK, Fried MW
    AGA Institute Clinical Practice Update: Care of Patients Who Have Achieved a Sustained Virologic Response (SVR) Following Antiviral Therapy for Chronic Hepatitis C Infection.
    Gastroenterology. 2017 Mar 23. pii: S0016-5085(17)30327.
    PubMed     Text format     Abstract available


  70. MISHRA P, Chen M
    Direct-Acting Antivirals for Chronic Hepatitis C: Can Drug Properties Signal Potential for Liver Injury?
    Gastroenterology. 2017 Mar 18. pii: S0016-5085(17)30295.
    PubMed     Text format    


  71. SAADOUN D, Pol S, Ferfar Y, Alric L, et al
    Efficacy and Safety of Sofosbuvir plus Daclatasvir for Treatment of HCV-associated Cryoglobulinemia Vasculitis.
    Gastroenterology. 2017 Mar 10. pii: S0016-5085(17)30269.
    PubMed     Text format     Abstract available


  72. COMARMOND C, Garrido M, Pol S, Desbois AC, et al
    Direct-acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus-induced Cryoglobulinemia Vasculitis.
    Gastroenterology. 2017 Mar 5. pii: S0016-5085(17)30235.
    PubMed     Text format     Abstract available


    February 2017
  73. AGHEMO A, Colombo M
    Response-Guided Duration of Directly Acting Antiviral Therapy for Chronic Hepatitis C: Back to the Future?
    Gastroenterology. 2017 Feb 27. pii: S0016-5085(17)30205.
    PubMed     Text format    


  74. JACOBSON IM, Lawitz E, Kwo PY, Hezode C, et al
    Safety and Efficacy of Elbasvir/Grazoprevir in Patients with Hepatitis C Virus Infection and Compensated Cirrhosis: an Integrated Analysis.
    Gastroenterology. 2017 Feb 10. pii: S0016-5085(17)30150.
    PubMed     Text format     Abstract available


  75. MATSUURA K, Sawai H, Ikeo K, Ogawa S, et al
    Genome-wide Association Study Identifies TLL1 Variant Associated With Development of Hepatocellular Carcinoma After Eradication of Hepatitis C Virus Infection.
    Gastroenterology. 2017 Feb 2. pii: S0016-5085(17)30130.
    PubMed     Text format     Abstract available


  76. RAVI S, Axley P, Jones D, Kodali S, et al
    Unusually High Rates of Hepatocellular Carcinoma After Treatment With Direct-Acting Antiviral Therapy for Hepatitis C Related Cirrhosis.
    Gastroenterology. 2017 Feb 1. pii: S0016-5085(16)35535.
    PubMed     Text format    


    January 2017
  77. GANE EJ, Hyland RH, Yang Y, Svarovskaia E, et al
    Efficacy of Ledipasvir Plus Sofosbuvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2 Infection.
    Gastroenterology. 2017 Jan 27. pii: S0016-5085(17)30074.
    PubMed     Text format     Abstract available


  78. GOLDBERG D, Ditah IC, Saeian K, Lalehzari M, et al
    Changes in the Prevalence of Hepatitis C Virus Infection, Non-alcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients with Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation.
    Gastroenterology. 2017 Jan 11. pii: S0016-5085(17)30014.
    PubMed     Text format     Abstract available


    December 2016
  79. KOUTSOUDAKIS G, Perez-Del-Pulgar S, Forns X
    Occult Hepatitis C Virus Infection: Are We Digging Too Deep?
    Gastroenterology. 2016 Dec 27. pii: S0016-5085(16)35528.
    PubMed     Text format    


  80. BOSON B, Denolly S, Turlure F, Chamot C, et al
    Daclatasvir Prevents Hepatitis C Virus by Blocking Transfer of Viral Genome to Assembly Sites.
    Gastroenterology. 2016 Dec 5. pii: S0016-5085(16)35447.
    PubMed     Text format     Abstract available


    November 2016
  81. LI F, Kaffenberger B, Hart PA
    An Unusual Rash During Evaluation for Chronic Pancreatitis.
    Gastroenterology. 2016 Nov 25. pii: S0016-5085(16)34961.
    PubMed     Text format    


  82. COLPITTS CC, Baumert TF
    SMAD about HCV cell entry and pathogenesis of liver disease.
    Gastroenterology. 2016 Nov 23. pii: S0016-5085(16)35398.
    PubMed     Text format    


  83. DONNELLY MC, Imlach SN, Abravanel F, Ramalingam S, et al
    Sofosbuvir and Daclatasvir Anti-Viral Therapy Fails to Clear HEV Viremia and Restore Reactive T Cells in a HEV/HCV Co-Infected Liver Transplant Recipient.
    Gastroenterology. 2016 Nov 21. pii: S0016-5085(16)34895.
    PubMed     Text format    


  84. ELMASRY S, Wadhwa S, Bang BR, Cook L, et al
    Detection of Occult Hepatitis C Virus Infection in Patients Who Achieved a Sustained Virologic Response to Direct-acting Antiviral Agents for Recurrent Infection After Liver Transplantation.
    Gastroenterology. 2016 Nov 9. pii: S0016-5085(16)35323.
    PubMed     Text format     Abstract available


  85. WANG W, Hakim MS, Nair VP, de Ruiter PE, et al
    Distinct Antiviral Potency of Sofosbuvir against Hepatitis C and E Viruses.
    Gastroenterology. 2016 Nov 1. pii: S0016-5085(16)35194.
    PubMed     Text format    


    October 2016
  86. KOMATSU TE, Boyd S, Sherwat A, Tracy L, et al
    Regulatory Analysis of Effects of Hepatitis C Virus NS5A Polymorphisms on Efficacy of Elbasvir and Grazoprevir.
    Gastroenterology. 2016 Oct 20. pii: S0016-5085(16)35241.
    PubMed     Text format     Abstract available


  87. LIANG TJ
    Hepatitis C Virus: from Obscurity to the Lasker.
    Gastroenterology. 2016 Oct 17. pii: S0016-5085(16)35233.
    PubMed     Text format    


  88. KWO P, Gane E, Peng CY, Pearlman B, et al
    Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients with Chronic Hepatitis C Infection.
    Gastroenterology. 2016 Oct 5. pii: S0016-5085(16)35170.
    PubMed     Text format     Abstract available


  89. AGHEMO A, Buti M
    Hepatitis C Therapy: Game Over!
    Gastroenterology. 2016 Oct 1. pii: S0016-5085(16)35131.
    PubMed     Text format    


    September 2016
  90. ZHANG F, Sodroski C, Cha H, Li Q, et al
    Infection of Hepatocytes with HCV Increases Cell Surface Levels of Heparan Sulfate Proteoglycans, Uptake of Cholesterol and Lipoprotein, and Virus Entry by Upregulating SMAD6 and SMAD7.
    Gastroenterology. 2016 Sep 29. pii: S0016-5085(16)35128.
    PubMed     Text format     Abstract available


  91. NAHON P, Bourcier V, Layese R, Audureau E, et al
    Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications.
    Gastroenterology. 2016 Sep 15. pii: S0016-5085(16)35070.
    PubMed     Text format     Abstract available


    April 2016
  92. BARRESI L, Ligresti D, Traina M
    A Challenging Diagnosis for a Biliary Stricture.
    Gastroenterology. 2016 Apr 29. pii: S0016-5085(16)00215.
    PubMed     Text format    


    February 2016
  93. SERFATY L
    Clinical implications of concomitant alcohol use, obesity and viral hepatitis.
    Gastroenterology. 2016 Feb 9. pii: S0016-5085(16)00139.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis C is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: